当前位置: 首页 >> 检索结果
49. Translational social medicine for global health: introducing Cases in Global Social Medicine.
作者: Seth M Holmes.;Mayssa Rekhis.;Scott D Stonington.;Mirko Pasquini.;Luke Messac.;Eugene Raikhel.;Junko Kitanaka.;Valéria Macedo.;Paola Sesia.;Carlos Piñones Rivera.;Tinashe Goronga.;Salmaan Keshavjee.;Benson A Mulemi.;Margareta Matache.;Michael Marmot.
来源: Lancet. 2025年406卷10517期2306-2307页 53. Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China.
作者: Jie Gao.;Mengtao Li.;Ming Sun.;Yiyi Yu.;Ruina Kong.;Xia Xu.;Suxuan Liu.;Qian Chen.;Xiaofang Li.;Yang Wu.;Enshun Xu.;Jianmin Yang.;Dongbao Zhao.
来源: Lancet. 2025年
Lately, autologous CD19-targeting chimeric antigen receptor (CAR) T cells have shown excellent efficacy in treatment of autoimmune diseases, but with great safety concerns, such as infections. In this study, we aimed to evaluate the safety, tolerability, and efficacy of allogeneic CD19 CAR natural killer (NK)-cell therapy in patients with relapsed or refractory systemic lupus erythematosus (SLE).
54. Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study.
作者: Mazen Noureddin.;Stephen A Harrison.;Rohit Loomba.;Naim Alkhouri.;Naga Chalasani.;Muhammad Y Sheikh.;Shaheen Tomah.;Julio A Gutierrez.;Silvia Urbina.;John J Suschak.;Randy Brown.;Ozioma Odili.;Jay Yang.;Stephine Keeton.;Guy Neff.;Edward Mena.;M Scot Roberts.;Sarah K Browne.;M Scott Harris.
来源: Lancet. 2025年
GLP-1-glucagon dual receptor agonists such as pemvidutide have shown promise in treating metabolic dysfunction-associated steatohepatitis (MASH). The aim of this trial was to assess the effects of pemvidutide on MASH resolution and fibrosis improvement in patients with liver fibrosis stage F2 or F3 MASH at 24 weeks of treatment.
56. Efficacy of once-daily, high-dose, oral insulin immunotherapy in children genetically at risk for type 1 diabetes (POInT): a European, randomised, placebo-controlled, primary prevention trial.
作者: Anette-Gabriele Ziegler.;Peter Achenbach.;Andreas Weiß.;Reinhard Berner.;Kristina Casteels.;Helena Elding Larsson.;Florian Haupt.;Angela Hommel.;An Jacobs.;Olga Kordonouri.;Markus Lundgren.;Mariusz Ołtarzewski.;Markus Pfirrmann.;Matthew D Snape.;Agnieszka Szypowska.;John A Todd.;Manu Vatish.;Thekla von dem Berge.;Christiane Winkler.;Ezio Bonifacio.; .
来源: Lancet. 2025年
Type 1 diabetes begins with autoimmunity against pancreatic islet antigens, including insulin. The aim of the Primary Oral Insulin Trial (POInT) was to evaluate the efficacy and safety of daily high-dose oral insulin to prevent the development of islet autoantibodies and diabetes.
59. The effects of government-led cash transfer programmes on behavioural and health determinants of mortality: a difference-in-differences study.
作者: Aaron Richterman.;Tra-My Ngoc Bùi.;Elizabeth F Bair.;Gregory Jerome.;Christophe Millien.;Jean Christophe Dimitri Suffrin.;Jere R Behrman.;Harsha Thirumurthy.
来源: Lancet. 2025年
Poverty is strongly associated with numerous adverse health outcomes. Government-led cash transfer programmes are crucial to poverty reduction strategies in many low-income and middle-income countries (LMICs). Although extensive research from individual programmes exists on the effects of cash transfers on beneficiaries, evidence of these programmes' population-wide health effects remains scarce. Previously, we showed that cash transfer programmes are associated with substantially reduced mortality rates among women and young children at the population level in LMICs. In this study, we aimed to explore the mechanisms underlying these reductions.
|